Institutional Ownership Adaptimmune Therapeutics PLC (ADAP)
This table provides information about the institutional ownership of Adaptimmune Therapeutics PLC (ADAP). We have compiled data on the 84 institutions that hold shares in the stock, with a total of 150 Million shares, which have been reported (via 13F filing form) to have a value of $85.4 Million.
| Holding | Report Date | shares Held | Holding Value (Reported) | Last Trade | Trade History |
|---|---|---|---|---|---|
|
Exane Derivatives
|
Jul 12, 2022 Q2 2022 |
121
shares
|
$71
0.0% of portfolio
|
Q3 2018
Reduced 99.1%
|
|
|
Investors Research Corp
|
Nov 12, 2024 Q3 2024 |
100
shares
|
$59
0.0% of portfolio
|
Q3 2023
Reduced 50.0%
|
|
|
Northwestern Mutual Wealth Management CO
|
Nov 12, 2024 Q3 2024 |
69
shares
|
$40
0.0% of portfolio
|
Q3 2024
New holding
|
|
|
Td Waterhouse Canada Inc.
Toronto, A6 |
Nov 12, 2024 Q3 2024 |
14
shares
|
$8
0.0% of portfolio
|
Q3 2024
New holding
|
|
|
Concourse Financial Group Securities, Inc.
Birmingham, AL |
Oct 10, 2024 Q3 2024 |
0
shares
|
$0
0.0% of portfolio
|
Q3 2024
New holding
|